P U L M O N A RY A RT E R I A L H Y P E RT E N S I O N T R EAT M E N T M A R K E T 2 0 1 8 BY M A N U FAC T U R E RS , FO R EC A ST TO 2 0 2 3 Published On : 26 Oct 2018
1
REPORT STUDIES The worldwide Pulmonary Arterial Hypertension Treatment Market is expected to grow at a CAGR of roughly % over the next five years, will reach xx million US$ in 2023, from million US$ in 2017. Pulmonary arterial hypertension– commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell functioneventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.
2
MARKET SEGMENT BY MANUFACTURERS • GlaxoSmithKline plc • Eli Lilly and Company • Pfizer Inc.Actelion Inc • United Therapeutic Corporation • SteadyMed Ltd • Gilead Sciences, Inc • Teva Pharmaceuticals Inc • Bayer AG
Add a Footer
3
MARKET SEGMENT BY REGIONS • North America (United States, Canada and Mexico) • Europe (Germany, France, UK, Russia and Italy) • Asia-Pacific (China, Japan, Korea, India and Southeast Asia) • South America (Brazil, Argentina, Colombia etc.) • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
4
APPLICATIONS
MARKET SEGMENT BY APPLICATIONS • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies
Hospital Pharmacies Online Pharmacies
Retail Pharmacies
5
TABLE OF CONTENTS 1. Market Overview 2. Manufacturers Profiles 3. Global Pulmonary Arterial Hypertension Treatment Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017) 4. Global Pulmonary Arterial Hypertension Treatment Market Analysis by Regions
6
Get in touch +91 8087042414 (Asia) +1 (646) 781 7170 (International)
TITLE Click here to know more about report https://www.grandresearchstore.com/lifesciences/global-pulmonary-arterial-hypertensiontreatment-2018-2023-669
help@grandresearchstore.com
www.grandresearchstore.com
Follow us:
7